Molunamax 200 Capsule


Product Info

Prescription required Yes
Marketer J B Chemicals and Pharmaceuticals Ltd
Active Ingredient Molnupiravir (200mg)
Chemical ClassCytosine Nucleotides
Habit FormingNo
Therapeutic ClassANTI INFECTIVES
Action ClassAntiviral (Non-HIV) drugs
User Rating4.6
User Reviews476

FAQ

Question
Are there any serious risks of taking Molunamax 200?
Yes, there are some serious risks involved with using Molunamax 200, including its potential to cause birth defects in pregnant women and serious damage to the growth of bones and cartilage (which may cause serious muscle damage). Therefore, Molunamax 200 should be used only if prescribed by a doctor and not used for self-medication.
Answer

Question
Who is at a high risk of developing severe COVID-19?
People who are at a high risk of developing severe COVID-19 include those aged above 60 years, who are obese, have comorbid conditions including high blood pressure, diabetes, asthma, other medical conditions related to the lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients).
Answer

Question
Is taking Molunamax 200 better than getting vaccinated?
No. There is no comparison between the two, and Molunamax 200 is not a substitute for getting vaccinated. Vaccination is for prevention, while Molunamax 200 is used to treat an existing COVID-19 infection, provided the infection is diagnosed at an early stage.
Answer

Question
Who should not take Molunamax 200?
Molunamax 200 should not be taken to prevent COVID-19 or treat patients hospitalized due to COVID-19. According to the ongoing clinical trials, patients hospitalized with severe COVID-19 infection have not benefited from taking Molunamax 200.
Answer

Question
What is the advantage of using Molunamax 200?
Molunamax 200 has better patient compliance than some other treatment options available against COVID-19. Unlike other medicines that may need a skilled healthcare professional (a doctor or a nurse) to administer, Molunamax 200 is an oral medicine that can be consumed by mouth in the dosage and schedule prescribed by the doctor.
Answer

Question
Can Molunamax 200 be given to children?
No, Molunamax 200 is not approved for use in children or patients below the age of 18 years as it may interfere with the growth of bones and cartilage.
Answer
Question
What if you forget to take Molunamax Capsule?
If you miss a dose of Molunamax 200, please consult your doctor.
Answer

Molunamax 200 Capsule Reviews

Molunamax 200 is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.

Molunamax 200 is only indicated in patients with mild to moderate COVID-19 symptoms and who have a high risk of developing severe symptoms. The risk factors include obesity, older age (>60 years), diabetes mellitus, and heart diseases. It is not indicated in patients who require immediate hospitalization due to COVID-19. This drug has also been approved by the U.S. Food and Drug Administration (FDA) and the UK regulatory agency for emergency use.

Molunamax 200 should be taken orally for no longer than 5 consecutive days. It is important to complete the entire 5 days of treatment, therefore do not stop taking it even if you feel better. The medicine may cause dizziness, headache, diarrhea, and nausea in some patients. If one experiences any such side effects, discuss them with the doctor. They may help with the treatment or suggest ways to prevent them.

Before taking Molunamax 200, let the doctor know if you have any pre-existing medical conditions. To make sure it is safe for you, inform your doctor about all the other medications you are taking. The use of Molunamax 200 is not recommended in pregnant women. Pregnant and breastfeeding women should consult with their doctors before taking this medicine.

How Molunamax 200 Capsule Works

Molunamax 200 is an antiviral medicine. It works by inhibiting the SARS-CoV-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.

How to Use Molunamax 200 Capsule

Take this medicine in the dose and duration as advised by your doctor. Molunamax 200 may be taken with or without food, but it is better to take it at a fixed time.

Benefits of Molunamax 200 Capsule

  • In Treatment of Mild to moderate Coronavirus disease (COVID-19): Molunamax 200 helps manage mild to moderate Covid-19 symptoms in those individuals who are at a high risk of developing severe Covid-19 disease and do not need oxygen administration. This medicine may help you recover from the infection if diagnosed early before hospitalization. If you think you have come in contact with a person who has been infected with Covid-19, or if you feel any of these symptoms, consult your doctor immediately.

Uses of Molunamax 200 Capsule

  • Treatment of Mild to moderate Coronavirus disease (COVID-19)

Molunamax 200 Capsule Side Effects

Item form

Safety Tips

Liver  SAFE IF PRESCRIBED
Molunamax 200 is safe to use in patients with liver disease. No dose adjustment of Molunamax 200 is recommended.
Pregnancy  CONSULT YOUR DOCTOR
Molunamax 200 may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Driving  CONSULT YOUR DOCTOR
It is not known whether Molunamax 200 alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Alcohol  CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Molunamax 200. Please consult your doctor.
Breast feeding  UNSAFE
Molunamax 200 is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Kidney  SAFE IF PRESCRIBED
Molunamax 200 is safe to use in patients with kidney disease. No dose adjustment of Molunamax 200 is recommended.

Quick Tips

  • Do not stop taking Molunamax 200 without talking to your doctor first, as it will protect you from becoming severely ill from COVID-19.
  • Even after the treatment, continue practicing COVID-appropriate behavior such as wearing a mask, social distancing, and frequent handwashing.
  • Do not give Molunamax 200 to children and adolescents aged less than 18 years.
  • For individuals with conceiving potential, it is advisable to use contraceptive methods while taking Molnupiravir and for 4 days after the last dose of the medicine.

References

  1. Molnupiravir [EMC SmPC]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021.
  2. EUnetHTA Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2020. Report No.: RCR19, v1.0.
  3. Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746.
  4. Molnupiravir. U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee November 30, 2021.
  5. FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. December 23, 2021.
  6. U.S. Food and Drug Administration: Center for Drug Evaluation and Research FDA Briefing Document, Antimicrobial Drugs Advisory Committee Meeting, November 30, 2021.
  7. Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India. Sun Pharma: Press Release.
  8. Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high risk of disease progression including hospitalization or death. Cipla: Press Statement.
  9. European Medicines Agency. Assessment Report: Use of molnupiravir for the treatment of COVID-19.
  10. Molnupiravir [Package leaflet: Information for the patient]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021.

Other Medical Preparations